Investigator-Initiated Research Grants

Nabriva Response to COVID-19

Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic.  Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics.  Xenleta^TM (lefamulin) may be an alternative regimen for patients in need.  Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors.  Learn more at www.XENLETA.com.

Again, to all the medical professionals, please be safe, take care of yourself and stay well.

Best,
Ted Schroeder
CEO, Nabriva Therapeutics

Continue to site